Related Experiment Video

Updated: Jul 4, 2025

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

439

[Annual updates of pulmonary infectious diseases in 2023]

G L Zhang1, J M Qu1

  • 1Department of Pulmonary and Critical Care Medicine, Rui-jin Hospital, Shanghai Jiaotong University School of Medicine,Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases,Institute of Respiratory Diseases, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China.

Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
|February 3, 2024
PubMed

Insights

In 2023, advances in understanding pulmonary infections, pathogen detection, and new treatments emerged despite challenges like antibiotic resistance and rising tuberculosis. Research focused on innovative drugs, vaccines, and rehabilitation for respiratory diseases.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Microbiology

Background:

  • Pulmonary infectious diseases pose a significant public health challenge globally.
  • Antibiotic resistance, increased tuberculosis cases, and fungal pneumonia post-viral infections complicate respiratory disease management.
  • Lagging control measures exacerbate the impact of these diseases.

Approach:

  • This review summarizes key research findings and advancements in 2023 concerning pulmonary infectious diseases.
  • It focuses on improvements in understanding disease pathogenesis, diagnostic technologies, and therapeutic strategies.
  • The review aims to provide insights for future research and healthcare initiatives.

Key Points:

  • Significant progress was made in understanding the pathogenesis of various pulmonary infections.
  • Pathogen detection technologies saw notable improvements, aiding in quicker diagnosis.
  • Development of novel antiviral and antibacterial drugs, alongside vaccine research, showed promise.
  • Advances in pulmonary rehabilitation methods were also highlighted.

Conclusions:

  • Despite ongoing challenges, 2023 witnessed crucial scientific breakthroughs in combating pulmonary infectious diseases.
  • These advances offer potential solutions for diagnosis, treatment, and prevention.
  • Continued research and healthcare initiatives are vital to address the evolving landscape of respiratory infections.

More Related Videos

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

10.8K
Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy09:24

Optical Screening of Novel Bacteria-specific Probes on Ex Vivo Human Lung Tissue by Confocal Laser Endomicroscopy

Published on: November 29, 2017

7.6K

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
225
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
329
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
332
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
239
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.3K